World Drug Report 2019

The 2019 World Drug Report will include an updated overview of recent trends on production, trafficking and consumption of key illicit drugs. The Report contains a global overview of the baseline data and estimates on drug demand and supply and provides the reference point for information on the drug situation worldwide.

Drawing on the Household Living Arrangements of Older Persons 2019 Dataset, the World Population Ageing 2020 Highlights will document key patterns and trends of the household living arrangements of older persons around the world.

The best country-by-country assessment of human rights. The human rights records of more than ninety countries and territories are put into perspective in Human Rights Watch's signature yearly report. Reflecting extensive investigative work undertaken by Human Rights Watch staff, in close partnership with domestic human rights activists, the annual World Report is an invaluable resource for journalists, diplomats, and citizens, and is a must-read for anyone interested in the fight to protect human rights in every corner of the globe.

The 2017 WDR will include an updated overview of recent trends on production, trafficking and consumption of key illicit drugs as well as highlighting a thematic area of concern. The Report will maintain a global overview of the baseline data and estimates on drug demand and supply. This part will be descriptive and less analytical to fulfill one of the main functions of the report which is to provide the reference point of information on the drug situation worldwide. Other parts will be more analytical and will look in depth at few specific topics. Issues which will be highlighted in analysing new trends were selected on the basis of available research findings discussed within RAB and other internal and external stakeholders, including the members of the WDR Scientific Advisory Committee (SAC). The thematic focus of the 2017 Report will be on the links between drugs, terrorism, corruption, transnational organized crime and illicit financial flows.

"Booklet 1 provides a summary of the four subsequent booklets by reviewing their key findings and highlighting policy implications based on their conclusions. Booklet 2 contains a global overview of the latest estimates of and trends in the supply, use and health consequences of drugs. Booklet 3 looks at recent trends in the market for depressants (including opioids, sedatives, tranquillizers and hypnotics), while Booklet 4 deals with recent trends in the market for stimulants (including cocaine, amphetamine-type stimulants and new psychoactive substances). Booklet 5 contains a review of recent trends in the market for cannabis and for hallucinogens. The section on cannabis also includes a review of the latest developments in the jurisdictions that have adopted measures allowing the non-medical use of cannabis."--Home page.

The ebook edition of this title is Open Access and freely available to read online. Examining the impact of drug criminalisation on a previously overlooked demographic, this book argues that women are disproportionately affected by a flawed policy approach.

Provides a key textbook on the nature of international and transnational crimes and the delivery of justice for crime control and prevention.

Illegal psychoactive substances and illicit prescription drugs are currently used on a daily basis all over the world. Affecting public health and social welfare, illicit drug use is linked to disease, disability, and social problems. Faced with an increase in usage, national and global policymakers are turning to addiction science for guidance on how to create evidence-based drug policy. Drug Policy and the Public Good is an objective analytical basis on which to build global drug policies. It presents the accumulated scientific knowledge on drug use in relation to policy development on a national and international level. By also revealing new epidemiological data on the global dimensions of drug misuse, it questions existing regulations and highlights the growing need for evidence-based, realistic, and coordinated drug policy. A critical review of cumulative scientific evidence, Drug Policy and the Public Good discusses four areas of drug policy; primary prevention programs in schools and other settings; supply reduction programs, including legal enforcement and drug interdiction; treatment interventions and harm reduction approaches; and control of the legal market through prescription drug regimes. In addition, it analyses the current state of global drug policy, and advocates improvements in the drafting of public health policy. Drug Policy and the Public Good is a global source of information and inspiration for policymakers involved in public health and social welfare. Presenting new research on illicit and prescription drug use, it is also an essential tool for academics, and a significant contribution to the translation of addiction research into effective drug policy.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.